Amicus Therapeutics Inc $7.08

down -0.19


29/8/2014 11:49 AM  |  NASDAQ : FOLD  
Industries : Drugs / Biotechnology
Get Trend Analysis Icon Get FOLD Trend Analysis - it has outperformed the S&P 500 by 173%

Partner Headlines

  1. Morning Market Movers

    Benzinga
  2. The Biotech Stock With The Best One-Week Performance

    Benzinga
  3. Stocks Hitting 52-Week Highs

    Benzinga
  4. Morning Market Movers

    Benzinga
  5. Benzinga's Top #PreMarket Gainers

    Benzinga
  6. Morning Market Movers

    Benzinga
  7. Amicus Extending Rally On Upgrades

    Benzinga
  8. Benzinga's Top Upgrades

    Benzinga
  9. Benzinga's Top #PreMarket Gainers

    Benzinga
  10. Morning Market Movers

    Benzinga
  11. Benzinga's Top #PreMarket Gainers

    Benzinga
  12. Earnings Scheduled For March 3, 2014

    Benzinga
  13. UPDATE: J.P. Morgan Downgrades Amicus Therapeutics On Cautious View of ...

    Benzinga
  14. Gilead Sciences Leads In Rising Short Interest Among Biotechs

    Benzinga
  15. Short Sellers Retreat From Biogen Idec, Move On Pharmacyclics (BIIB, BMRN, ...

    Benzinga
  16. BioMarin, Celgene Lead Trend in Biotech Short Interest (BRMN, CELG, REGN)

    Benzinga
  17. Amicus, Biogen Announce Deal for Discovery, Development, Commercialization ...

    Benzinga
  18. Amicus Therapeutics Says Added 6-Month Results from Phase 3 Fabry Monotherapy ...

    Benzinga
  19. Amicus Therapeutics Advances Chaperone-ERT Combo Platform in Pompe Diesease

    Benzinga
  20. Amicus Announces Positive Phase 2 Results for Chaperone-Enzyme Replacement ...

    Benzinga
  21. Stocks Hitting 52-Week Lows

    Benzinga
  22. UPDATE: Wedbush Downgrades Amicus Therapeutics to Underperform on Phase ...

    Benzinga
  23. Option Traders Call a Bottom for Amicus Therapeutics

    SchaeffersResearch
  24. GlaxoSmithKline

    IBD
  25. Amicus, Glaxo Release Top-Line Six-Month Primary Treatment Period Results ...

    Benzinga
  26. Amicus Therapeutics Announces Additional Preliminary Results from Open ...

    Benzinga
  27. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q)

    GuruFocus
  28. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-Q)

    GuruFocus
  29. UPDATE: Canaccord Reiterates Buy Rating, Raises PT on Amicus Therapeutics

    Benzinga
  30. Amylin Pharmaceuticals, Best Buy Among Stocks Up on High Volume Monday

    FoxBusiness
  31. Benzinga's Top Upgrades with Color for May 8, 2012

    Benzinga
  32. UPDATE: J.P. Morgan Upgrades Amicus Therapeutics

    Benzinga
  33. From Earlier: Amicus Therapeutics Prices Underwritten Offering of 10M Shares ...

    Benzinga
  34. AMICUS THERAPEUTICS, INC. Reports Operating Results (10-K)

    GuruFocus
  35. Amicus Therapeutics Presents Preclinical Studies of Chaperone AT3375 for ...

    Benzinga
  36. Amicus Therapeutics Announces Positive Preliminary Results From Ongoing ...

    Benzinga
Trading Center